Core Viewpoint - Treace Medical Concepts, Inc. (TMCI) shareholders may have been impacted by potential fraudulent activities, prompting an investigation by Levi & Korsinsky [1] Group 1: Company Overview - Treace Medical Concepts, Inc. is under scrutiny for possible fraud that could affect its shareholders [1] - The investigation is being conducted by the law firm Levi & Korsinsky, which specializes in shareholder rights [1] Group 2: Investigation Details - The investigation aims to determine if TMCI misled investors regarding its business practices and financial performance [1] - Shareholders are encouraged to reach out to the law firm to discuss their rights and potential claims [1]

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations ...

Company Investigation - Levi & Korsinsky is investigating whether Treace Medical Concepts Inc (TMCI) misled investors [1] - The investigation focuses on potential misleading statements or omissions by the company [1] - Shareholder rights advocates are involved in the probe [1] Legal Context - The investigation is being conducted by a law firm specializing in shareholder rights [1] - The probe is in its early stages with no conclusions yet [1] - The investigation could potentially lead to legal action if wrongdoing is found [1]

Core Viewpoint - Treace Medical Concepts, Inc. is under investigation for potential violations of securities laws, prompting affected investors to reach out to the Schall Law Firm for assistance [1] Group 1 - The investigation into Treace Medical Concepts, Inc. suggests possible legal issues that could impact the company's reputation and financial standing [1] - Affected investors are encouraged to contact legal representation, indicating a significant concern regarding the company's compliance with securities regulations [1]

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Fraud ...

Financial Results - Treace Medical Concepts, Inc. reported preliminary unaudited financial results for the quarter and year ended December 31, 2024[7]. Upcoming Events - The company plans to present at the J.P. Morgan Healthcare Conference on January 14, 2025, at 9:00 am Pacific Time[9]. - An investor presentation was posted on the company's investor relations website on January 13, 2025[9].

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approxi ...

Core Insights - Treace Medical Concepts, Inc. has launched the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, following the introduction of other innovative products aimed at enhancing surgical procedures in the foot and ankle sector [1][4][6]. Company Developments - The Percuplasty System is designed for minimally invasive correction of bunion deformities, allowing for precise 3D corrections through small incisions, which reduces pain and recovery time compared to traditional surgeries [6][7]. - The system targets a significant market, with nearly 450,000 bunion surgeries performed annually in the U.S., 70% of which involve metatarsal osteotomies, positioning Treace Medical to capture a larger market share and increase revenues [8]. - The company anticipates full commercialization of the Percuplasty System in the second half of 2025 [2]. Financial Performance - Treace Medical currently has a market capitalization of $492.2 million, with a Zacks Consensus Estimate for fiscal 2024 revenues at $207.6 million, reflecting a growth of 10.9% from fiscal 2023 [5]. Industry Outlook - The global bunion correction systems market is projected to reach $1.2 billion by 2030, with a compound annual growth rate (CAGR) of 6.9% from 2023 to 2030, driven by the rising prevalence of bunions and an increasing number of procedures [9].

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am ...

Company Overview - Treace Medical Concepts Inc is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities [13] - The company has pioneered and patented the Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions [13] - Treace estimates that 1 1 million of the 67 million Americans affected by bunions are annual surgical candidates [13] - The company has introduced additional products including the Adductoplasty Midfoot Correction System and SpeedPlate Rapid Compression Implants [13] Product Development - The Percuplasty Percutaneous 3D Bunion Correction System represents the company's second entry into the metatarsal osteotomy segment, which accounts for approximately 70% of the 450,000 bunion surgeries performed annually in the US [2] - Full commercialization of the Percuplasty System is anticipated in the second half of 2025 [10] - The Percuplasty System follows the limited release of the Nanoplasty System, providing an additional solution in the large metatarsal osteotomy segment of the $5B+ US bunion market opportunity [12] Market Strategy - The limited market release of the Percuplasty System positions the company to significantly increase its share of the overall bunion market and expand its surgeon customer base [17] - The company aims to provide a comprehensive portfolio of instrumented 3D bunion systems to meet the evolving needs of surgeons and patients [12] - The Percuplasty System is designed to expand surgeon and patient access to the improved recovery and cosmetic benefits of percutaneous bunion surgery [15] Industry Context - Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot [13] - The metatarsal osteotomy segment is the largest segment of the bunion market [2] - There is growing patient demand for minimally invasive (MIS) bunion surgery [15]